Endo International PLC (NASDAQ:ENDP)‘s stock had its “outperform” rating restated by research analysts at JMP Securities in a research note issued to investors on Friday. They presently have a $34.00 target price on the stock, down from their previous target price of $44.00. JMP Securities’ price objective indicates a potential upside of 94.51% from the company’s current price.

A number of other brokerages have also issued reports on ENDP. Mizuho upgraded shares of Endo International PLC from a “neutral” rating to a “buy” rating and increased their target price for the company from $16.00 to $29.00 in a research report on Friday, August 12th. Vetr upgraded shares of Endo International PLC from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 21st. Susquehanna upgraded shares of Endo International PLC from a “neutral” rating to a “positive” rating and set a $20.00 price objective for the company in a research report on Thursday. Zacks Investment Research upgraded shares of Endo International PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, July 20th. Finally, Morgan Stanley set a $15.00 price objective on shares of Endo International PLC and gave the company a “hold” rating in a research report on Friday, August 5th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $33.69.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Endo International PLC (NASDAQ:ENDP) opened at 17.48 on Friday. The firm’s 50-day moving average is $19.69 and its 200-day moving average is $19.15. Endo International PLC has a 12 month low of $12.56 and a 12 month high of $63.71. The firm’s market cap is $3.89 billion.

Endo International PLC (NASDAQ:ENDP) last announced its earnings results on Tuesday, November 8th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.20. The firm earned $894.30 million during the quarter, compared to analyst estimates of $862.47 million. Endo International PLC had a negative net margin of 3.32% and a positive return on equity of 15.95%. Endo International PLC’s revenue was up 18.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.02 EPS. Equities analysts expect that Endo International PLC will post $4.55 earnings per share for the current year.

Several large investors have recently made changes to their positions in ENDP. Heartland Advisors Inc. bought a new stake in shares of Endo International PLC during the second quarter valued at about $15,627,000. State Street Corp increased its stake in shares of Endo International PLC by 9.3% in the second quarter. State Street Corp now owns 9,430,866 shares of the company’s stock valued at $147,021,000 after buying an additional 805,101 shares during the last quarter. Schneider Capital Management Corp bought a new stake in shares of Endo International PLC during the second quarter valued at about $6,941,000. Quantitative Investment Management LLC increased its stake in shares of Endo International PLC by 166.2% in the second quarter. Quantitative Investment Management LLC now owns 654,800 shares of the company’s stock valued at $10,208,000 after buying an additional 408,800 shares during the last quarter. Finally, Alps Advisors Inc. bought a new stake in shares of Endo International PLC during the second quarter valued at about $4,877,000. Institutional investors and hedge funds own 96.61% of the company’s stock.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

5 Day Chart for NASDAQ:ENDP

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.